EVENITY

EVENITY at a Glance

EVENITY® is a once-monthly injectable treatment for postmenopausal osteoporosis at high fracture risk. It works by inhibiting sclerostin, increasing bone formation and reducing resorption.

• Dose: 210 mg SC, given as two 105 mg injections once monthly
• Use limit: 12 doses (1 year max)
• Mechanism: Dual-action—bone formation + anti-resorption

Performance Benefits for Clinical Use

EVENITY delivers rapid BMD increases and reduces fracture risk across high-risk patient populations.

• 73% relative reduction in new vertebral fractures at 12 months
• 75% reduction in vertebral fractures at 24 months with follow-up antiresorptive use
• 13% increase in lumbar spine BMD at 12 months
• 8.1% lumbar spine BMD gain sustained at 24 months with sequential alendronate
• Outperforms alendronate in BMD gains and fracture prevention

Ideal EVENITY Use Cases and Patient Profiles

Indicated for postmenopausal women with osteoporosis at high risk for fracture—especially those who:

• Have a prior osteoporotic fracture
• Have multiple fracture risk factors
• Are intolerant or unresponsive to other osteoporosis treatments

Note: Not for patients with MI or stroke in the past year

EVENITY Core Ingredients and Their Roles

Each prefilled syringe contains romosozumab-aqqg, a humanized monoclonal antibody.

• Active: Romosozumab-aqqg 105 mg/1.17 mL
• Excipients: Sucrose, calcium, acetate, polysorbate 20, sodium hydroxide, water for injection
• pH adjusted to 5.2

EVENITY Injection Techniques and Application Guide

EVENITY must be administered by a healthcare professional. Each monthly dose requires two injections.

• Dose: 210 mg SC monthly, via two 105 mg prefilled syringes
• Sites: Abdomen, thigh, or upper arm
• Rotate injection sites; avoid irritated or scarred skin
• Missed dose: Reschedule promptly; resume monthly from new date
• Supplement with calcium and vitamin D throughout treatment

EVENITY Storage, Shelf Life, and Handling

Proper storage is critical for drug stability and efficacy.

• Refrigerate at 2–8°C (36–46°F) in original carton
• Do not freeze or shake
• At room temp (max 25°C/77°F): stable for up to 30 days
• Inspect prior to use: solution should be clear to light yellow, free of particles

EVENITY Side Effects: What to Monitor

Monitor patients for both common and serious events.

Common (≥5%):

• Arthralgia
• Headache

Serious:

• Cardiovascular: MI, stroke, cardiovascular death—hazard ratio 1.87 vs alendronate
• Hypocalcemia: Especially in renal impairment; correct before starting
• ONJ and atypical femoral fractures: Evaluate dental health and thigh/groin pain
• Hypersensitivity: Angioedema, rash, urticaria—discontinue if reaction occurs

Key Practitioner Questions About EVENITY Answered

How long can EVENITY be used?

• 12 months max. Afterward, transition to an antiresorptive agent.

Is it effective alone?

• Yes, but follow-up with denosumab or alendronate sustains BMD gains.

Can patients self-inject?

• No. Must be administered by a licensed provider.

Is it safe in renal impairment?

• No dose adjustment needed, but monitor calcium in severe impairment or dialysis.

What happens after stopping?

• Without follow-up treatment, BMD returns to baseline within 12 months

How to Order EVENITY for Your Practice

EVENITY is a prescription biologic available via licensed distributors for in-clinic administration.

Contact Doctor Medica’s customer service representatives for guidance on how to order Evenity online.